Compare ASYS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASYS | CNTB |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 164.5M | 128.6M |
| IPO Year | 2006 | 2020 |
| Metric | ASYS | CNTB |
|---|---|---|
| Price | $12.98 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | ★ 171.8K | 110.5K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.22 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $79,364,000.00 | $26,033,000.00 |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $18.75 | $24,617.69 |
| P/E Ratio | $1,278.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.20 | $0.51 |
| 52 Week High | $18.59 | $3.28 |
| Indicator | ASYS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 48.02 | 51.52 |
| Support Level | $11.60 | $2.09 |
| Resistance Level | $13.26 | $2.86 |
| Average True Range (ATR) | 0.79 | 0.20 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 47.20 | 44.78 |
Amtech Systems Inc provides equipment, consumables and services for semiconductor device packaging, wafer production and device fabrication. Its products are used to fabricate and package GPUs for AI applications, SiC and Si power devices, and other optical, analog and digital devices, and are sold to semiconductor packaging, electronic assembly and device fabrication companies. It operates through two segments: Thermal Processing Solutions, which includes conveyorized reflow equipment, high-temperature conveyorized furnaces and diffusion furnaces with maximum revenue; and Semiconductor Fabrication Solutions, which includes consumables, equipment and services for wafer polishing, dicing and cleaning. The majority of revenue is derived from the United States.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.